PharmaFocus Today – Page 30 – media

CanSino accelerates global deployment of dual vaccines

The reporter recently learned from CanSinoIt is learned that on September 29, CanSino’s independently developed 13-valent pneumococcal polysaccharide conjugate vaccine PCV13i and Asia’s first quadrivalent meningococcal polysaccharide conjugate vaccine MCV4 were shipped to the domestic and overseas markets respectively. CanSino Biologics’ independently developed 13-valent pneumococcal polysaccharide conjugate vaccine, Upexin®, was officially approved by the National Medical Products Administration in June of this year. It is China’s first pneumococcal polysaccharide conjugate vaccine to utilize a dual vector consisting of an avirulent mutant of diphtheria toxin (CRM197) and tetanus toxoid (TT). This vaccine provides enhanced protection against the four serotypes (19F, 19A, 7F, and 3) that carry the heaviest burden of pneumococcal disease in children in China. It is reported that by 2026, Upexin® will expand its reach into the domestic market, with overseas expansion also in the works. When Youpexin® was shipped domestically, Asia’s first ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector) Manhaixin® also ...
- Source: drugdu
- 157
- October 3, 2025
Lencaneluzumab biosimilar approved for clinical trials for the treatment of Alzheimer’s disease

Sinopharm announced that its subsidiary, Jushi Biopharmaceuticals Co., Ltd., of CSPC Pharmaceutical Group, has received the “Notice of Approval for Clinical Trial of Lencanelumab Injection” from the National Medical Products Administration (NMPA). Clinical trials of the drug will commence soon. Lencanelumab Injection is a recombinant anti-human amyloid-β monoclonal antibody and a biosimilar to Leyibao, indicated for the treatment of mild cognitive impairment and mild dementia caused by Alzheimer’s disease. The product approved for clinical trials by Sinopharm is the first biosimilar to lencanelumab injection to obtain clinical approval in China . Currently, there are only a handful of new Alzheimer’s disease drugs on the market, such as Lencaneluzumab and Donezetimumab, all developed by multinational pharmaceutical companies and relatively expensive. The clinical approval of domestically produced biosimilars suggests the potential for improved patient accessibility and reduced financial burdens in the future. Source: https://cj.sina.cn/articles/view/5953189932/162d6782c06703893e?froms=ggmp
- Source: drugdu
- 85
- October 3, 2025
New molecular sensor for taste-based detection of influenza

Flu season is fast approaching in the northern hemisphere. And a taste-based influenza test could someday have you swapping nasal swabs for chewing gum. A new molecular sensor has been designed to release a thyme flavor when it encounters the influenza virus. Researchers reporting in ACS Central Science say that they plan to incorporate this type of low-tech sensor into gum or lozenges to increase at-home screenings and potentially prevent pre-symptomatic transmission of the disease. Staying home is critical to preventing the spread of infectious diseases like influenza; however, people with the flu are contagious before they develop symptoms. Current flu diagnostics like nasal swab-based PCR tests are accurate, but they are slow and expensive. At-home lateral flow tests, akin to those used to test for COVID-19, are convenient and generally low-cost, but don’t catch pre-symptomatic infections. As written in their published study, Lorenz Meinel and colleagues address these flu ...
- Source: drugdu
- 79
- October 3, 2025
FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis

The approval is for pediatric patients living with either moderate-to-severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis. This approval expands indications of use beyond the initial adult population and is the first and only pediatric approval for an interleukin-23 inhibitor. The approval is based on results from the phase 3 PROTOSTAR study in which the coprimary end points of Psoriasis Area Severity Index (PASI) 90 and Investigator’s Global Assessment (IGA) score of 0/1 were achieved at week 16. More than half of patients (56 percent) receiving Tremfya achieved PASI 90 versus 16 percent of patients receiving placebo. For IGA score, at week 16, two-thirds (66 percent) of patients receiving Tremfya achieved high levels of skin clearance (score 0/1) versus 16 percent of patients receiving placebo. Complete clearance (IGA 0) at week 16 was achieved by nearly 40 percent of pediatric patients receiving Tremfya ...
- Source: drugdu
- 98
- October 3, 2025
New study reveals molecular basis of Long COVID brain fog

Even though many years have passed since the start of the COVID-19 pandemic, the effects of infection with SARS-CoV-2 are not completely understood. This is especially true for Long COVID, a chronic condition that can develop after COVID-19 that causes a variety of lasting symptoms. Among the most common and debilitating of these is cognitive impairment, often referred to as “brain fog,” which affects over 80% of people with Long COVID. Given the hundreds of millions of global cases, Long COVID represents a massive public health and socioeconomic challenge, as it severely impacts people’s ability to work and perform daily activities. Unfortunately, despite its prevalence, the underlying causes of Long COVID and brain fog remain poorly understood. Previous imaging studies have shown some structural changes in the brain, but they could not pinpoint the molecular dysfunctions responsible for the cognitive symptoms. Since it’s difficult to observe the molecules that govern ...
- Source: drugdu
- 103
- October 2, 2025
HPV Vaccine Protecting Against Infections, Even Among Unvaccinated

Depending on which vaccine they received, HPV infections fell by 76% to 98% over 17 years among vaccinated women, researchers reported in the journal JAMA Pediatrics. But infections also fell by 72% to 76% among unvaccinated women during the same period, results showed. “There are two encouraging takeaways from our study,” said senior researcher Dr. Jessica Kahn, chair of head and neck pathology at the Albert Einstein College of Medicine in New York City. “First, HPV vaccines work remarkably well in a real-world setting, even among women at high risk for HPV and who may not have received all vaccine doses,” she said in a news release. “Second, we saw clear evidence of herd immunity, meaning when enough people are vaccinated, the vaccine indirectly protects unvaccinated people by reducing overall virus transmission.” Kahn said these results “reinforce the potential of the HPV vaccine to prevent infection and, ultimately, eliminate cervical cancer globally.” Long-lasting ...
- Source: drugdu
- 101
- October 2, 2025
The company’s Phase III clinical study of the nine-valent HPV vaccine is ongoing.

an investor asked on the investor interaction platform: When is the company’s nine-valent vaccine expected to be launched? What is its current stage? What is the annual production capacity of the company’s production line? Watson Bio(300142.SZ) stated on the investor interaction platform on September 24 that the company’s related work on the Phase III clinical study of the nine-valent HPV vaccine is ongoing. If there is any substantial and phased progress in the research and development of the company’s vaccine, the company will disclose it in a timely manner. Please pay attention to the relevant information disclosed by the company for subsequent progress. Source；https://finance.eastmoney.com/a/202509243522306220.html
- Source: drugdu
- 173
- October 2, 2025
The company has acquired a controlling stake in Chenan Bio by increasing capital this year.

SecuritiesDaily News Zhifei BiologyWhen answering investors’ questions on the interactive platform on September 26, it was stated that the company had achieved controlling stake in Chenan Bio through capital increase this year, and the company’s business had extended from vaccines to metabolic diseases. Source：https://finance.eastmoney.com/a/202509263524977168.html
- Source: drugdu
- 108
- October 2, 2025
CKBA Cream, a subsidiary of the holding company, has been approved for clinical trials for rosacea.

Taienkang announced that its controlling subsidiary, Broad Venture Park, has received a “Notice of Approval for Drug Clinical Trial” from the National Medical Products Administration (NMPA), authorizing the conduct of a Phase II/III seamless adaptive clinical trial of CKBA Cream for the rosacea indication. CKBA Cream is a topical preparation independently developed by Broad Venture Park and is a Category 1 innovative chemical drug. To date, no Category 1 innovative drug for the treatment of rosacea has been approved for marketing in China . Tainkang’s innovative drug has been approved for clinical trials and is expected to fill the treatment gap for rosacea indications in China . If clinical trials can prove its efficacy, the market potential is considerable. Source：https://www.stcn.com/article/detail/3358450.html
- Source: drugdu
- 92
- October 2, 2025
Another indication for ADC bispecific antibody Iza-Bren has been included in the Breakthrough Therapy List

Baili Tianheng issued an announcement stating that the company’s independently developed iza-bren (EGFR×HER3 dual-antibody ADC), the world’s first, new concept and the only one to enter the Phase III clinical stage, is used for patients with unresectable locally advanced or metastatic urothelial carcinoma who have failed previous treatment with platinum-containing chemotherapy and PD-1/PD-L1 inhibitors. It has been included in the list of breakthrough therapies by the Drug Review Center of the National Medical Products Administration. To date, seven indications of Iza-bren have been included in the list of breakthrough therapies by the Center for Drug Evaluation, and one indication has been granted breakthrough therapy designation by the U.S. Food and Drug Administration. The National Medical Products Administration’s Center for Drug Evaluation prioritizes resources for drugs included in the Breakthrough Therapy designation, strengthening guidance and promoting drug development. Baili Tianheng’s Iza-bren has been designated a Breakthrough Therapy, which is expected to ...
- Source: drugdu
- 131
- October 2, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.